Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel C Mok

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Neoplasia (New York, N.Y.)|June 8, 2006
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancerJoseph Kwong, Ji-Young Lee, Kwong-Kwok Wong, et al.
Gynecologic Oncology|August 3, 2005
Potential markers that complement expression of CA125 in epithelial ovarian cancerDaniel G Rosen, Lin Wang, J Neeley Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2017
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin MattersJanelle B Pakish, Qian Zhang, Zhongyuan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2019
Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic CancerTsz-Lun Yeung, Cecilia S Leung, Kay-Pong Yip, et al.
JAMA|April 3, 2002
Osteopontin as a potential diagnostic biomarker for ovarian cancerJae-Hoon Kim, Steven J Skates, Toshimitsu Uede, et al.
Cancer Research|September 5, 2006
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancerJan S Sunde, Howard Donninger, Kongming Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk womenAsha Rathi, Arvind K Virmani, John O Schorge, et al.
Cancer Immunology, Immunotherapy : CII|September 14, 2019
Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signatureEmily Hinchcliff, Cherie Paquette, Jason Roszik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urineBin Ye, Steven Skates, Samuel C Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomasColleen M Feltmate, Kenneth R Lee, Michael Johnson, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Neoplasia (New York, N.Y.)|June 8, 2006
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancerJoseph Kwong, Ji-Young Lee, Kwong-Kwok Wong, et al.
Gynecologic Oncology|August 3, 2005
Potential markers that complement expression of CA125 in epithelial ovarian cancerDaniel G Rosen, Lin Wang, J Neeley Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2017
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin MattersJanelle B Pakish, Qian Zhang, Zhongyuan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2019
Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic CancerTsz-Lun Yeung, Cecilia S Leung, Kay-Pong Yip, et al.
JAMA|April 3, 2002
Osteopontin as a potential diagnostic biomarker for ovarian cancerJae-Hoon Kim, Steven J Skates, Toshimitsu Uede, et al.
Cancer Research|September 5, 2006
Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancerJan S Sunde, Howard Donninger, Kongming Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk womenAsha Rathi, Arvind K Virmani, John O Schorge, et al.
Cancer Immunology, Immunotherapy : CII|September 14, 2019
Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signatureEmily Hinchcliff, Cherie Paquette, Jason Roszik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urineBin Ye, Steven Skates, Samuel C Mok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomasColleen M Feltmate, Kenneth R Lee, Michael Johnson, et al.
Pageof 15